Public healthcare programs reimburse costs for majority of dialysis treatments in the United States and in Western Europe. The governments of these regions are considering proposals for controlling costs by altering the public-sponsored healthcare programs. This move is likely to change the profitability of the dialysis industry which has been banking on the rapid increase in the number of dialysis patients globally.
The dialysis care market has seen major growth in the last few years and in this segment – the most preferred method of treatment continues to be hemodialysis which accounts for about 90% of all dialysis therapies. Another mode of treatment - peritoneal dialysis remains the preferred method for about 10% of all dialysis patients.
The dialysis care market has also seen rapid consolidation over the last decade and this has resulted in the emergence of only top-notch players. Two significant acquisitions – acquisition of Renal Care Group by Fresenius Medical Care and acquisition of Gambro by DaVita has changed the competitive landscape of the dialysis industry. Fresenius and DaVita are now the undisputed leaders in the dialysis services sector.
However, it is Fresenius Medical Care which has shown tremendous growth in the past few years and clinched market shares in both dialysis care and dialysis products market.
The report analyzes the dialysis market with focus on both the dialysis care and dialysis products market. It is a study of the growth of dialysis globally and the popular methods of treatments for dialysis. The report analyzes the two major segments of the dialysis services sector – hemodialysis and peritoneal dialysis. It also assesses the ownership structure of the dialysis care providers – the presence of publicly owned and private companies in major regions. The level of competition in both the markets – dialysis care and dialysis products has been extensively covered in the report. The report also presents an outlook for the dialysis industry worldwide.
